|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
|
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current assets | ||||||||
| Cash | ||||||||
| Prepaid expenses | ||||||||
| Deferred offering costs | ||||||||
| Total current assets | ||||||||
| Long term prepaid insurance | ||||||||
| Long-term prepaid insurance | ||||||||
| Cash and marketable securities held in Trust Account | ||||||||
| TOTAL ASSETS | ||||||||
| LIABILITIES AND SHAREHOLDERS’ DEFICIT | ||||||||
| Current liabilities | ||||||||
| Accrued expenses | ||||||||
| Due to related party | ||||||||
| Promissory note - related party | ||||||||
| Accrued offering costs | ||||||||
| Total current liabilities | ||||||||
| Deferred underwriting fee payable | ||||||||
| Deferred Fee payable | ||||||||
| TOTAL LIABILITIES | ||||||||
| Class A Ordinary Shares subject to possible redemption, 23,000,000 and 23,000,000 shares at redemption value of $10.77 and $10.58 per share at June 30, 2026 and December 31, 2025, respectively | ||||||||
| SHAREHOLDERS’ DEFICIT | ||||||||
| Ordinary shares value | ||||||||
| Additional paid-in capital | ||||||||
| Accumulated deficit | ||||||||
| TOTAL SHAREHOLDERS’ DEFICIT | ||||||||
| TOTAL LIABILITIES AND SHAREHOLDERS’ DEFICIT |
Loading...
